A brief male sexual function inventory for urology

O’Leary, Michael P.; Fowler, Floyd J.; Lenderking, William R.; Barber, Beth; Sagnier, Pierre P.; Guess, Harry A.; Barry, Michael J.

doi:10.1016/s0090-4295(99)80304-5

Cited by 415 publications

(291 citation statements)

References 13 publications

Supporting

Mentioning

266

Contrasting

Unclassified

Order By: Relevance

“…These data were in contradiction to those observed in a long-term ®nasteride study with regard to stimulation sexual function. 41 It is important to distinguish clinical sexual score assessment 42 from the patient's perception of his sexual life. In BPH a majority of patients do not complain about sexual function, but are still interested in treatments that are supposed to interfere least with their sexual life status.…”

Section: Discussionmentioning

confidence: 99%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Objectives: To investigate (a) the magnitude and durability of symptom score reduction and HRQL score improvement (including sexual drive); (b) adverse outcomes; and (c) progression to acute urinary retention and prostate surgery up to three years of treatment with alfuzosin.Methods: Three thousand two hundred and twenty-eight BPH-patients out of 812 centers were included in a prospective three-year open-labelled study and treated with alfuzosin (immediate release formulation) at the recommended dosage. A symptom score (Boyarsky modi®ed) and a 20-item BPH speci®c HRQL score including three questions of sexuality (Urolife TM BPH QoL 20) were selfadministered at baseline, 3,6,12,18,24,30, and 36 months.Results: Two thousand ®ve hundred and seventy-nine patients (79.9%) completed the study at the end of three years. Symptom score was signi®cantly reduced by 54% at 3 months and this reduction was maintained up to 36 months (748.4%); HRQL score was signi®cantly improved by 45.4% at 12 months and this improvement was maintained up to 36 months ( 43.4%). Alfuzosin was well tolerated: the quantitative and qualitative distribution of adverse events was similar to that previously observed in placebo-controlled studies (vertigo/dizziness: 2.1%). Adverse events accounted for 4.2% of the drop-outs. 120 patients (3.7%) were operated on for BPH and nine patients (0.3%) experienced acute urinary retention.Conclusion: This medical outcomes study con®rms the long-term safety pro®le of alfuzosin in the naturalistic conditions of general practice and highlights the need to measure HRQL in the context of patient's preferences.

show abstract

Section: Discussionmentioning

confidence: 99%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Clinical questionnaires have been developed (e.g. [2,3]), but asking sensitive questions in a primary provider's office, once the patient has sought treatment, is far different from administering a standardized instrument as a stranger in the field.…”

Section: Introductionmentioning

confidence: 99%

A new surrogate variable for erectile dysfunction status in the Massachusetts male aging study

Kleinman

Feldman

Johannes

et al. 2000

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

Erectile dysfunction (ED) is the subject of a vast clinical literature, but little information has been gathered from random samples of the general public. The Massachusetts Male Aging Study (MMAS) addressed this important aspect of men's health. The MMAS was conducted in two waves, with baseline data collection in 1987-1989 and follow-up in 1995-1997. Subsequent to the baseline MMAS survey, a consensus developed that subjective measures are optimal for defining ED. Unfortunately, the baseline questionnaire did not ask subjects directly about their erectile functioning. Thus, we previously assigned the MMAS subjects a degree of impotence at baseline using a series of related questions, employing a discriminant formula constructed from a separate sample of urology clinic patients. At follow-up the men classified themselves directly in addition to answering the original series of related questions. In the present article, we report the results of a new discriminant function, based on the MMAS men at follow-up. We also compare the two methods and discuss our reasons for preferring the internally calibrated method.

show abstract

“…The Brief Sexual Function Inventory (SFI) 7 The International Index of Erectile Function (IIEF) 8 Urolife Scale 9 The Danish Prostatic Symptom Score (DAN-PSS) 10,11 Of these, the SFI and the IIEF have been developed specifically to measure male sexual function.…”

Section: Evaluation Of Sexual Functionmentioning

confidence: 99%

Impact of treatment of BPH on sexuality

Schulman

2001

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) can have a profound affect on a patient's quality of life and sexual function and is considered by patients to be one of the most important aspects affected by the disease. Different treatments can produce a variable response in terms of the patient's quality of life, including sexual activity and satisfaction. Varying rates of erectile dysfunction (ED) and retrograde ejaculation following surgery for BPH have been reported. In general, the incidence of these side-effects is less after minimally invasive therapies, such as interstitial laser coagulation and transurethral microwave therapy, but the data available are limited. The lowest rates of sexual dysfunction are reported with medical therapies. The 5a-reductase inhibitor, finasteride, can result in ED in 5 -9% of patients and ejaculation disorders in 0.8 -2.0%. With the exception of tamsulosin, a 1 blockers are associated with a low rate of sexual dysfunction. No cases of ED have been reported with alfuzosin and abnormal ejaculation with terazosin or alfuzosin is negligible. Indeed, early research suggests a beneficial effect of a 1 blockers on sexual function. In addition to information on the efficacy of a particular therapy, patients should be informed of side effects, in particular those relating to sexual function, in order that they can make informed treatment decisions. Prostate Cancer and Prostatic Diseases (2001) 4, Suppl 1, S12-S16.

show abstract

A brief male sexual function inventory for urology

Cited by 415 publications

References 13 publications

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

A new surrogate variable for erectile dysfunction status in the Massachusetts male aging study

Impact of treatment of BPH on sexuality

Contact Info

Product

Resources

About